{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methylene blue
to a specific field?
Status:
Investigational
Source:
NCT00695448: Phase 1 Interventional Terminated Solid Tumours
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
GSK 1059615, a pyridinylquinoline derivative, is a novel PI3K kinase and mTOR dual inhibitor. GSK1059615 was in phase I clinical trial in patients with solid tumors or lymphoma, but this study was terminated prematurely due to lack of sufficient exposure following single- and repeat dosing. In addition, recently was shown, that GSK 1059615 in xenograft mice models possessed anti-head and neck squamous cell carcinoma (HNSCC) cell activity.
Status:
Investigational
Source:
INN:arfolitixorin [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
METHYLENETETRAHYDROFOLIC ACID, L-(+), an endogenous biomodulator that was developed under the brand name modufolin or arfolitixorin by the Isofol Medical. Arfolitixorin is developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. This drug is currently being studied in a global phase 3 clinical trial. Besides, the drug successfully completed phase II as rescue therapy for osteosarcoma. 21 May 2019 Isofol Medical has received clinical patent protection for the arfolitixorinin USA. It relates to a method of increasing blood concentration of deoxyuridine, a blood biomarker for inhibition of tumor growth in human cancer treatment.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifuradene (NF-246), a chemotherapeutic
nitrofuran, was first synthesized and reported
in 1956. Nifuradene, a 5-Nitorofuran derivative, is an antibacterial drug. Early in vitro testing
found it an effective chemotherapeutic agent
against most of the common urinary pathogens. Subsequent in vivo studies found that this compound is well absorbed after oral administration
in both animals and humans. Nifuradene was used for the treatment of urinary tract infections. The over-all cure rate was found
to be best at doses exceeding 600 mg a day.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifuratrone is a nitrofuran which was used for the control of Salmonella choleraesuis in swine. It was also used for the treatment of gonorrhea.
Status:
Investigational
Source:
NCT01922843: Phase 2 Interventional Completed Hyperparathyroidism, Secondary
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:redafamdastat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
PF-04457845 is a fatty acid amide hydrolase 1 inhibitor developed by Pfizer for the treatment of inflammatory and noninflammatory pain disorders. The drug was tested in phase II in patients with osteoarthritis of the knee, but found to have the same effect as placebo. It was also assessed in phase II clinical trial for its effect on marijuana withdrawal and Tourette syndrome.
Status:
Investigational
Source:
NCT00322673: Phase 2 Interventional Terminated Acute Myeloid Leukemia
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00475683: Phase 3 Interventional Completed Chemotherapy Induced Mucositis
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Curcumol is one of the major components of the essential oil of Rhizome Curcumae with the structure of sesquiterpenoid hemiketal. It exhibits characteristics such as antitumor, ant proliferation, anti-inflammatory, anti-hepatic fibrosis, antioxidant, and antimicrobial activities with low cytotoxicity. Curcumol suppresses the Breast Cancer Cells, Colorectal Cancer Cell Line, lung adenocarcinoma cell lines and others. However, its effect and mechanisms against tumor metastasis are still unclear. Recently was discovered a preliminary mechanism the suppression of breast cancer cell metastasis by curcumol. This mechanism suggested the inhibition of MMP-9 via JNK1/2 and Akt (Ser473)-dependent NF-κB signaling pathways.
Status:
Investigational
Source:
NCT03838185: Phase 1 Interventional Completed Alzheimer's Disease
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00508664: Phase 2 Interventional Completed Squamous Cell Carcinoma of the Hypopharynx
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Neotetrazolium chloride is used for the histochemical detection of dehydrogenases. Neotetrazolium reduction can be used for discriminating malignant cells from nonmalignant cells. Neotetrazolium chloride is used for the colorimetric estimation of succinic dehydrogenase activity in a tumor sensitivity test to chemotherapeutic agents. Neotetrazolium chloride is also used in the microagglutination test and in the Neotetrazolium Test (NTC) for histologic evaluation of myocardial sections in acute necrobiosis of the myocardium.
